Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 2/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16156452 | 0.93 | SIRT2 (0.42) | FURINSIRT2SIRT1ROCK2SIRT3 | |
| SCHEMBL15686242 | 0.87 | NMT2 (0.45) | CTSLFURINCALCRLKLKB1ROCK2 | |
| SCHEMBL19687799 | 0.87 | SIRT2 (0.42) | FURINSIRT2SIRT1ROCK2SIRT3 | |
| SCHEMBL19687798 | 0.87 | SIRT2 (0.42) | FURINSIRT2SIRT1ROCK2SIRT3 | |
| SCHEMBL18556695 | 0.87 | SIRT2 (0.42) | FURINSIRT2SIRT1SIRT3HTT | |
| SCHEMBL14887361 | 0.87 | SIRT2 (0.42) | FURINSIRT2SIRT1ROCK2SIRT3 | |
| SCHEMBL16091818 | 0.86 | SIRT2 (0.41) | FURINSIRT2SIRT1SIRT3HTT | |
| SCHEMBL15606204 | 0.86 | SIRT2 (0.41) | FURINSIRT2SIRT1ROCK2SIRT3 | |
| SCHEMBL26257608 | 0.85 | SIRT2 (0.43) | CTSLFURINSIRT2SIRT1ROCK2 | |
| SCHEMBL19647265 | 0.85 | SIRT2 (0.42) | FURINSIRT2SIRT1SIRT3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136299-A1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | GENZYME CORPORATION | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136299-A1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | CD2BP2, B3GAT3, SIGLEC7 | CTSL 2085/4885FURIN 421/4885CALCRL 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.